AIA Group Ltd Has $6.54 Million Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

AIA Group Ltd boosted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 14.2% in the 1st quarter, HoldingsChannel.com reports. The firm owned 8,460 shares of the biopharmaceutical company’s stock after buying an additional 1,052 shares during the quarter. AIA Group Ltd’s holdings in Regeneron Pharmaceuticals were worth $6,537,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of REGN. Nordea Investment Management AB increased its stake in Regeneron Pharmaceuticals by 118.1% in the fourth quarter. Nordea Investment Management AB now owns 137,321 shares of the biopharmaceutical company’s stock valued at $105,810,000 after purchasing an additional 74,350 shares in the last quarter. Lockheed Martin Investment Management Co. bought a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth $2,702,000. Asio Capital LLC bought a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth $3,422,000. National Pension Service grew its holdings in shares of Regeneron Pharmaceuticals by 29.8% in the 4th quarter. National Pension Service now owns 360,988 shares of the biopharmaceutical company’s stock valued at $278,636,000 after buying an additional 82,853 shares during the period. Finally, Robeco Institutional Asset Management B.V. grew its holdings in shares of Regeneron Pharmaceuticals by 116.6% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 261,850 shares of the biopharmaceutical company’s stock valued at $202,114,000 after buying an additional 140,966 shares during the period. Institutional investors own 83.31% of the company’s stock.

Key Headlines Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Negative Sentiment: Multiple law firms announced or promoted securities class-action activity tied to REGN, including a newly filed class action and related investor deadline notices. These developments can weigh on sentiment because they highlight alleged disclosure issues and raise the risk of legal costs or settlement uncertainty. Article: Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Regeneron Pharmaceuticals, Inc. (REGN)
• Negative Sentiment: Additional reminders from Faruqi & Faruqi, Robbins LLP, Levi & Korsinsky, and Bragar Eagel & Squire kept the lawsuit story in focus, reinforcing legal overhang for shareholders. Article: REGN Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Filed Against Regeneron Pharmaceuticals, Inc.
• Neutral Sentiment: A market commentary piece said Regeneron has rebounded and may still look undervalued, but also questioned whether the upside is already reflected in the shares, making the stock’s near-term direction less clear. Article: Regeneron Pharmaceuticals (REGN) Rebounds As Undervalued View Holds, Is The Upside Already Priced In?
• Neutral Sentiment: Brokerage coverage cited by American Banking News said REGN carries a “Moderate Buy” consensus, which supports the long-term outlook but is less likely to move the stock immediately than the litigation headlines. Article: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Consensus Rating of “Moderate Buy” by Brokerages

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock opened at $676.69 on Monday. Regeneron Pharmaceuticals, Inc. has a 52-week low of $541.00 and a 52-week high of $821.11. The stock has a market cap of $71.54 billion, a price-to-earnings ratio of 16.49, a PEG ratio of 1.50 and a beta of 0.24. The firm’s 50-day moving average is $640.99 and its 200-day moving average is $717.97. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.96 and a current ratio of 3.57.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, topping the consensus estimate of $8.91 by $0.56. The company had revenue of $3.61 billion during the quarter, compared to the consensus estimate of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The firm’s revenue for the quarter was up 19.0% compared to the same quarter last year. During the same period in the previous year, the company posted $8.22 EPS. Sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.12 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th were given a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend was Wednesday, May 20th. Regeneron Pharmaceuticals’s payout ratio is 9.16%.

Wall Street Analysts Forecast Growth

Several analysts recently commented on REGN shares. Canaccord Genuity Group dropped their price objective on Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating on the stock in a research note on Tuesday, May 19th. Weiss Ratings reissued a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, June 24th. Truist Financial lowered their price target on Regeneron Pharmaceuticals from $778.00 to $769.00 and set a “buy” rating for the company in a report on Tuesday, July 7th. Sanford C. Bernstein dropped their target price on shares of Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating on the stock in a report on Wednesday, April 8th. Finally, Cantor Fitzgerald dropped their price target on Regeneron Pharmaceuticals from $785.00 to $750.00 and set an “overweight” rating on the stock in a research note on Monday, July 6th. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $787.67.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 200 shares of the company’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total value of $130,030.00. Following the transaction, the director directly owned 17,303 shares in the company, valued at $11,249,545.45. The trade was a 1.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.